Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Revenue of iTeos Therapeutics, Inc. (ITOS)
Revenue in 2023 (TTM): $12.6 M
According to iTeos Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $12.6 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of iTeos Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $12.6 M | $11.7 M | $-143,989,000 | $-109,030,000 | $-112,642,000 |
| 2022 | $267.63 M | $266.82 M | $130.39 M | $148.74 M | $96.65 M |
| 2021 | $344.78 M | $344.16 M | $255.69 M | $256.46 M | $214.52 M |
| 2020 | $ | $-535,000 | $-38,772,000 | $-38,090,000 | $-38,033,000 |
| 2019 | $ | $-611,000 | $-21,724,000 | $-22,335,000 | $-22,454,000 |
| 2018 | $ | $-505,000 | $-17,475,000 | $-18,046,000 | $-18,057,000 |